Proactive Investors - Run By Investors For Investors

Summit’s CDI hails “key” patent win in Europe

Drug developer Summit Therapeutics (LON:SUMM) has been awarded a European patent for ridinilazole, its new antibiotic for C.Difficile infection.

Speaking to Proactive, director of corporate communications, Richard Pye, said: “This is a very key development for our ridinilazole antibiotic programme because it means now we have patent protection, not just in Europe, but also the other major commercial markets.”

The next stage, he said, is for the treatment to move into Phase III trials, with two studies, which will look to confirm the previous Phase II proof of concept results.

Meet Amur Minerals Corporation, Lekoil Ltd, SDX Energy Inc and Tethyan Resources PLC at our event, London, 19 October 2017. Register here »
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

October 04 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use